Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD

Autor: Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K

Publikováno v: International Journal of COPD, Vol Volume 12, Pp 3055-3064 (2017)

Christer Janson,1 Georgios Stratelis,1,2 Anna Miller-Larsson,3 Tim W Harrison,4 Kjell Larsson5 1Respiratory, Allergy and Sleep Research Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 2Respiratory, Inflammation and Autoimmu

Externí odkaz: https://doaj.org/article/73039059b297418998fa58e5d0142a63

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.

Autor: Louis R; Department of Pneumology CHU Liége, GIGAI3, University of Liége, Liége, Belgium., Harrison TW; Respiratory Research Unit, Nottingham Respiratory NIHR BRC, University of Nottingham, Nottingham, UK; Global Medical Affairs, AstraZeneca, Cambridge, UK. Electronic address: Tim.Harrison@nottingham.ac.uk., Chanez P; Department of Respiratory CIC Nord INSERMINRAE C2VN, Aix Marseille University, Marseille, France., Menzella F; Pulmonology Unit, S. Valentino Hospital, Local Health Authority, Montebelluna, Italy., Philteos G; Royal University Hospital, University of Saskatchewan, Saskatoon, Sask, Canada., Cosio BG; Hospital Son Espases-IdISBa and Ciberes, Palma de Mallorca, Spain., Lugogo NL; University of Michigan, Ann Arbor, Mich., de Luiz G; Clinical Research and Respiratory Medicine Department, Vithas Xanit International Hospital, Benalmadena, Málaga, Spain., Burden A; Biometrics, Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Adlington T; Biometrics, Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Keeling N; BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden., Kwiatek J; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Del., Garcia Gil E; BioPharmaceuticals Medical, AstraZeneca, Barcelona, Spain.

Publikováno v: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2023 Jun; Vol. 11 (6), pp. 1759-1770.e7. Date of Electronic Publication: 2023 Mar 21.

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial.

Autor: Harrison TW (AUTHOR), Oborne J (AUTHOR), Newton S (AUTHOR), Tattersfield AE (AUTHOR), Harrison, T W¹ (AUTHOR), Oborne, J (AUTHOR), Newton, S (AUTHOR), Tattersfield, A E (AUTHOR)

Publikováno v: Lancet. 1/24/2004, Vol. 363 Issue 9405, p271-275. 5p.

Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.

Autor: Busby J; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Matthews JG; 23 and Me, Sunnyvale, CA, USA., Chaudhuri R; NHS Greater Glasgow and Clyde Health Board, Gartnavel General Hospital and University of Glasgow, Glasgow, UK., Pavord ID; Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, The University of Oxford, Oxford, UK., Hardman TC; Niche Science & Technology Ltd, London, UK., Arron JR; Genentech Inc., South San Francisco, CA, USA., Bradding P; Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK., Brightling CE; Dept of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK., Choy DF; Genentech Inc., South San Francisco, CA, USA., Cowan DC; NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, UK., Djukanovic R; School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK., Hanratty CE; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Harrison TW; Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK., Holweg CT; Genentech Inc., South San Francisco, CA, USA., Howarth PH; School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK., Fowler SJ; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Lordan JL; The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK., Mansur AH; University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Menzies-Gow A; Royal Brompton and Harefield NHS Foundation Trust, London, UK., Niven RM; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Robinson DS; University College Hospitals NHS Foundation Trust, London, UK., Walker SM; Asthma UK and British Lung Foundation Partnership, London, UK., Woodcock A; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Heaney LG; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK l.heaney@qub.ac.uk.

Publikováno v: The European respiratory journal [Eur Respir J] 2021 Sep 24; Vol. 59 (4). Date of Electronic Publication: 2021 Sep 24 (Print Publication: 2022).

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.

Autor: Harrison TW; Respiratory Research Unit, Nottingham National Institute for Health Research Biomedical Research Centre, University of Nottingham; Nottingham City Hospital, Nottingham, UK. Electronic address: tim.harrison@nottingham.ac.uk., Chanez P; Department of Respiratory Diseases CIC Nord INSERM, INRAE, C2VN, Aix Marseille University, Marseille, France., Menzella F; Pneumology Unit, Santa Maria Nuova Hospital, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy., Canonica GW; Humanitas University & Research Hospital, IRCCS, Milano, Italy., Louis R; University and Centre Hospitalier Universitaire of Liège, Liège, Belgium., Cosio BG; Hospital Son Espases-IdISBa and Ciberes, Palma de Mallorca, Spain., Lugogo NL; University of Michigan Medical Center, Ann Arbor, MI, USA., Mohan A; East Carolina University Brody School of Medicine, Greenville, NC, USA., Burden A; AstraZeneca, Cambridge, UK., McDermott L; AstraZeneca, Gaithersburg, MD, USA., Garcia Gil E; AstraZeneca, Barcelona, Spain., Zangrilli JG; AstraZeneca, Gaithersburg, MD, USA.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Mar; Vol. 9 (3), pp. 260-274. Date of Electronic Publication: 2020 Dec 22.